Zolpidem half-life
Zolpidem labeling supports a short parent half-life around 2.5 hours in healthy adults.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.
Zolpidem: evidence and interpretation notes
What the representative value means
Zolpidem labeling supports a short parent half-life around 2.5 hours in healthy adults. Age, sex, hepatic impairment, formulation, and next-day function can all diverge from that simple center.
A 2.5-hour input gives this profile one auditable line for Zolpidem. The line deliberately stops short of claims about clinical effect, measured concentration, or testing results.
Zolpidem is a sedative-hypnotic where a relatively short half-life can still be clinically important because timing, dose, and patient factors influence next-day effects.
The 2.5 hour value gives a short sleep-medication curve. It does not predict complex sleep behaviors, impairment, or safety-sensitive performance.
The citations include a direct DailyMed zolpidem label and the compound record.
This page is not sleep-treatment advice or a next-day driving calculator.
For Zolpidem, a shorter half-life can still be relevant for next-day functioning. Age, dose, sleep timing, and co-medications can change real-world residual effects.
What each source contributes
- DailyMed: Zolpidem tartrate tablet. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- PubChem: Zolpidem. This identity record confirms names and compound identity and does not supply a human half-life.
For Zolpidem, the numerical model is tied most closely to DailyMed: Zolpidem tartrate tablet. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.
Why there is no range on the chart
This profile plots 2.5 hours for Zolpidem without adding an unsourced high-low band. A single supported center is more honest than manufacturing a range from unrelated routes, populations, or formulations.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 2.5 h as a representative input for Zolpidem. In the simplified model, about 0.1% remains after 24 hours and about 3% remains after five half-lives, or roughly 12.5 h.
This is a short curve. The modeled amount changes noticeably over the same day, while effects, metabolites, and safety questions can still follow a different timeline. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
sedative-hypnotic context
Sedative-hypnotic half-life estimates may not reflect next-day impairment, active metabolites, or effects from combined central nervous system depressants.
- Half-life does not equal safe timing for activities.
- Combination effects are outside the calculator model.
- Formulation and route can change onset and peak.
ComparisonTimeline checkpoints and nearby profiles
Zolpidem timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 6 h | 18.9% | Long-tail portion of the model |
| 12 h | 3.59% | Low modeled remainder, not a clearance guarantee |
| 24 h | 0.13% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Zolpidem within the sedative-hypnotic group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Zopiclone / Eszopiclone (5 h)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 2.5 h |
|---|---|
| Curve type | Normalized, first-order decline |
Selection note: Zolpidem labeling supports a short parent half-life around 2.5 hours in healthy adults. Age, sex, hepatic impairment, formulation, and next-day function can all diverge from that simple center.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: Zolpidem tartrate tablet.Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Identity record PubChem Compound Summary: Zolpidem.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the sedative-hypnotic group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.